China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion Oct 19 (Reuters) - China's Hansoh Pharmaceutical 3692.HK said on Monday its units have entered into a collaboration and licensing deal with Roche ROPC.S potentially worth more than $15 billion, covering a portfolio of antibody-drug conjugate programs.
Under the deal, Hansoh will receive an upfront payment of $400 million, a first anniversary payment of $110 million, and further milestone payments.
(Reporting by Nichiket Sunil in Bengaluru; Editing by Leroy Leo)
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion